Consensus recommendations for the classification and long-term follow up of infants who screen positive for Krabbe Disease.
dc.contributor.author | Thompson-Stone, Robert | |
dc.contributor.author | Ream, Margie A | |
dc.contributor.author | Gelb, Michael | |
dc.contributor.author | Matern, Dietrich | |
dc.contributor.author | Orsini, Joseph J | |
dc.contributor.author | Levy, Paul A | |
dc.contributor.author | Rubin, Jennifer P | |
dc.contributor.author | Wenger, David A | |
dc.contributor.author | Burton, Barbara K | |
dc.contributor.author | Escolar, Maria L | |
dc.contributor.author | Kurtzberg, Joanne | |
dc.date.accessioned | 2022-03-23T21:04:28Z | |
dc.date.available | 2022-03-23T21:04:28Z | |
dc.date.issued | 2021-09 | |
dc.date.updated | 2022-03-23T21:04:28Z | |
dc.description.abstract | ObjectiveTo provide updated evidence and consensus-based recommendations for the classification of individuals who screen positive for Krabbe Disease (KD) and recommendations for long-term follow-up for those who are at risk for late onset Krabbe Disease (LOKD).MethodsKD experts (KD NBS Council) met between July 2017 and June 2020 to develop consensus-based classification and follow-up recommendations. The resulting newly proposed recommendations were assessed in a historical cohort of 47 newborns from New York State who were originally classified at moderate or high risk for LOKD.ResultsInfants identified by newborn screening with possible KD should enter one of three clinical follow-up pathways (Early infantile KD, at-risk for LOKD, or unaffected), based on galactocerebrosidase (GALC) activity, psychosine concentration, and GALC genotype. Patients considered at-risk for LOKD based on low GALC activity and an intermediate psychosine concentration are further split into a high-risk or low-risk follow-up pathway based on genotype. Review of the historical New York State cohort found that the updated follow-up recommendations would reduce follow up testing by 88%.ConclusionThe KD NBS Council has presented updated consensus recommendations for efficient and effective classification and follow-up of NBS positive patients with a focus on long-term follow-up of those at-risk for LOKD. | |
dc.identifier | S1096-7192(21)00083-4 | |
dc.identifier.issn | 1096-7192 | |
dc.identifier.issn | 1096-7206 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartof | Molecular genetics and metabolism | |
dc.relation.isversionof | 10.1016/j.ymgme.2021.03.016 | |
dc.subject | Humans | |
dc.subject | Leukodystrophy, Globoid Cell | |
dc.subject | Neonatal Screening | |
dc.subject | Risk Factors | |
dc.subject | Follow-Up Studies | |
dc.subject | Consensus | |
dc.subject | Genotype | |
dc.subject | Infant | |
dc.subject | Infant, Newborn | |
dc.subject | Practice Guidelines as Topic | |
dc.subject | Dried Blood Spot Testing | |
dc.subject | Late Onset Disorders | |
dc.title | Consensus recommendations for the classification and long-term follow up of infants who screen positive for Krabbe Disease. | |
dc.type | Journal article | |
duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 | |
pubs.begin-page | 53 | |
pubs.end-page | 59 | |
pubs.issue | 1-2 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
pubs.publication-status | Published | |
pubs.volume | 134 |
Files
Original bundle
- Name:
- p383 Thompson-Stone.pdf
- Size:
- 289.95 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version